GRI Bio, Inc. 8-K

What Happened

• On January 28, 2026, GRI Bio, Inc. announced additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis (IPF) via a press release. The company filed a Current Report on Form 8-K (Item 8.01) to disclose the announcement and attached the press release as Exhibit 99.1. The Form 8-K was signed by Chief Financial Officer Leanne Kelly.

Key Details

• Filing date: January 28, 2026 (Form 8-K, Item 8.01).
• Subject: Additional clinical data from the Phase 2a trial of GRI-0621 in IPF patients.
• Disclosure: Press release attached as Exhibit 99.1 to the Form 8-K.
• No financial statements or material agreements were reported in this filing.

Why It Matters

• For investors, new clinical data from a Phase 2a trial are material because they can affect the company’s clinical outlook, development timeline and investor sentiment.
• The 8-K notifies the market of the data release but does not itself provide detailed trial results in the filing; investors should review the attached press release and follow-up company disclosures for specific efficacy, safety, or next-step information.